Viridian Therapeutics, Inc.

VRDN

$732M

Small Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaWALTHAM143 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 1, 2026

21d

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

4 upcoming, 0 past

⭐Phase 3Next

VRDN-003 Phase 3 Results Expected

Mar 1, 2026VRDN-003117

Primary completion for VRDN-003 trial (NCT06625411) in Thyroid Eye Disease

Source

⭐Phase 3

VRDN-003 Phase 3 Results Expected

Apr 1, 2026VRDN-003195

Primary completion for VRDN-003 trial (NCT06812325) in Thyroid Eye Disease (TED)

Source

⭐Phase 3

VRDN-003 Phase 3 Results Expected

April 2026~VRDN-003321

Primary completion for VRDN-003 trial (NCT06812325) in Thyroid Eye Disease (TED)

Source

⭐Phase 3

VRDN-003 Phase 3 Results Expected

July 2026~VRDN-00387

Primary completion for VRDN-003 trial (NCT07155668) in Thyroid Eye Disease

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

VRDN-001 10 mg/kg

Phase 3

Thyroid Eye Disease

Intervention/Treatment

Phase 3

Thyroid Eye Disease

VRDN-001 Phase 3 Cohort (THRIVE)

Phase 3

Thyroid Eye Disease

Veligrotug (VRDN-001)

Phase 3

Thyroid Eye Disease

VRDN-003

Phase 3

Thyroid Eye Disease

Drug Name	Phase	Indication	Designations
VRDN-001 10 mg/kg	Phase 3	Thyroid Eye Disease	-
Intervention/Treatment	Phase 3	Thyroid Eye Disease	-
VRDN-001 Phase 3 Cohort (THRIVE)	Phase 3	Thyroid Eye Disease	-
Veligrotug (VRDN-001)	Phase 3	Thyroid Eye Disease	-
VRDN-003	Phase 3	Thyroid Eye Disease	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

VRDN News